药品风险分担协议对中国大陆的启示——以澳大利亚、新西兰、中国台湾为例

摘要

With the rapid development of healthcare technologies, the improvement of patient health expecta-tions, and the increasing of the government or insurer's financial budget pressure, risk-sharing agreements has be-come the focus of the governments or insurer concerned. This article systematically analyzed Australia, New Zealand, Taiwan risk-sharing agreements from five aspects, including the operation main, scope, classification, application processes and the implementation effects. According to the results of the analysis, we suggests that China should im-prove risk-sharing agreements theoretical basis, diversify risk-sharing agreements models, establish risk-sharing a-greements standardization process and so on.%在新医疗技术不断推陈出新,药品疗效和效果存在不确定性,患者健康期望值增加以及政府和保险机构面临财政预算压力的背景下,风险分担协议逐渐成为许多国家政府或保险机构关注的焦点.本文将从主管机构、适用范围、类型划分、应用流程、实施效果5个方面分析澳大利亚、新西兰和中国台湾的药品风险分担协议政策,提出我国应完善药品风险分担协议理论基础、多样化风险分担协议类型、标准化风险分担协议流程等内容,以进一步完善我国药物政策.